Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2017, Article ID 7053959, 5 pages
https://doi.org/10.1155/2017/7053959
Research Article

TSH Variability of Patients Affected by Differentiated Thyroid Cancer Treated with Levothyroxine Liquid Solution or Tablet Form

1Department of Medical and Surgical Sciences, Endocrine and Metabolic Unit, Clinica Medica, 2nd Medicina, Spedali Civili di Brescia, University of Brescia, 25123 Brescia, Italy
2Department of Molecular and Translational Medicine, 3rd Division of General Surgery, Spedali Civili di Brescia, University of Brescia, 25123 Brescia, Italy
3Department of Otorhinolaryngology, Spedali Civili di Brescia, 25123 Brescia, Italy

Correspondence should be addressed to Carlo Cappelli; ti.sbinu@illeppac.olrac

Received 29 December 2016; Revised 13 March 2017; Accepted 22 March 2017; Published 9 May 2017

Academic Editor: Franco Veglio

Copyright © 2017 Carlo Cappelli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Pujol, J. P. Daures, N. Nsakala, L. Baldet, J. Bringer, and C. Jaffiol, “Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer,” Journal of Clinical Endocrinology & Metabolism, vol. 81, no. 11, pp. 4318–4071, 1996. View at Publisher · View at Google Scholar
  2. J. Jonklaas, N. J. Sarlis, D. Litofsky et al., “Outcomes of patients with differentiated thyroid carcinoma following initial therapy,” Thyroid, vol. 16, no. 12, pp. 1229–1242, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. B. R. Haugen, E. K. Alexander, K. C. Bible et al., “2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer,” Thyroid, vol. 26, no. 1, pp. 1–133, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. J. S. Harrop, K. Ashwell, and M. R. Hopton, “Circannual and within-individual variation of thyroid function tests in normal subjects,” Annals of Clinical Biochemistry, vol. 22, no. 4, pp. 371–375, 1985. View at Publisher · View at Google Scholar
  5. S. Andersen, K. M. Pedersen, N. H. Bruun, and P. Laurberg, “Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease,” Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 3, pp. 1068–1072, 2002. View at Publisher · View at Google Scholar
  6. Z. C. Hannoush and R. E. Weiss, “Thyroid hormone replacement in patients following thyroidectomy for thyroid cancer,” Rambam Maimonides Medical Journal, vol. 7, no. 1, pp. 1–9, 2016. View at Publisher · View at Google Scholar
  7. IMS National Prescription Audit™, The Use of Medicines in the United States: Review of 2010, IMS Institute for Healthcare Informatics, Parsippany, NJ, USA, 2011, https://www.imshealth.com.
  8. G. J. Canaris, N. R. Manowitz, G. Mayor, and E. C. Ridgway, “The Colorado thyroid disease prevalence study,” Archives of Internal Medicine, vol. 160, no. 4, pp. 526–534, 2000. View at Publisher · View at Google Scholar
  9. J. V. Parle, J. A. Franklyn, K. W. Cross, S. R. Jones, and M. C. Sheppard, “Thyroxine prescription in the community: serum thyroid stimulating hormone level assays as an indicator of undertreatment or overtreatment,” British Journal of General Practice, vol. 43, no. 368, pp. 107–109, 1993. View at Google Scholar
  10. R. Negro, R. Valcavi, D. Agrimi, and K. A. Toulis, “Levothyroxine liquid solution versus tablet for replacement treatment in hypothyroid patients,” Endocrine Practice, vol. 20, no. 9, pp. 901–906, 2014. View at Publisher · View at Google Scholar
  11. C. Cappelli, I. Pirola, L. Daffini, E. Gandossi, B. Agosti, and M. Castellano, “Thyroid hormonal profile in elderly patients treated with two different levothyroxine formulations: a single institute survey,” European Geriatric Medicine, vol. 5, no. 6, pp. 382–385, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Fallahi, S. M. Ferrari, and A. Antonelli, “Oral L-thyroxine liquid versus tablet in patients with hypothyroidism without malabsorption: a prospective study,” Endocrine, vol. 52, no. 3, pp. 597–601, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, D. S. Cooper, G. M. Doherty et al., “Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer,” Thyroid, vol. 19, no. 11, pp. 1167–1214, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Liwanpo and J. M. Hershman, “Conditions and drugs interfering with thyroxine absorption,” Best Practice & Research Clinical Endocrinology & Metabolism, vol. 23, no. 6, pp. 781–792, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Li, X. L. Du, L. R. Reitzel, L. Xu, and E. M. Sturgis, “Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: review of incidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980–2008,” Thyroid, vol. 23, no. 1, pp. 103–110, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Van den Bruel, J. Francart, C. Dubois et al., “Regional variation in thyroid cancer incidence in Belgium is associated with variation in thyroid imaging and thyroid disease management,” Journal of Clinical Endocrinology & Metabolism, vol. 98, no. 10, pp. 4063–4071, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Giusti, L. Mortara, N. Machello, E. Monti, G. Pera, and M. Marenzana, “Utility of a liquid formulation of levo-thyroxine in differentiated thyroid cancer patients,” Drug Research, vol. 65, no. 6, pp. 332–336, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. R. M. Tuttle and R. Leboeuf, “Follow up approaches in thyroid cancer: a risk adapted paradigm,” Endocrinology Metabolism Clinics of North America, vol. 37, no. 2, pp. 419–435, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Biondi and D. S. Cooper, “Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer,” Thyroid, vol. 20, no. 2, pp. 135–146, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Giusti, G. Melle, M. Fenocchio et al., “Five-year longitudinal evaluation of quality of life in a cohort of patients with differentiated thyroid carcinoma,” Journal of Zheijang University. Science B, vol. 12, no. 3, pp. 163–173, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. E. N. Klein Hesselink, M. S. Klein Hesselink, G. H. de Bock et al., “Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study,” Journal of Clinical Oncology, vol. 31, no. 32, pp. 4046–4053, 2013. View at Publisher · View at Google Scholar
  22. C. T. Sawin, A. Geller, P. A. Wolf et al., “Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons,” The New England Journal of Medicine, vol. 331, no. 19, pp. 1249–1252, 1994. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Vadiveloo, P. T. Donnan, L. Cochrane, and G. P. Leese, “The Thyroid Epidemiology, Audit, and Research Study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism,” Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 5, pp. 1344–1351, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Patanè and F. Marte, “Atrial fibrillation associated with exogenous subclinical hyperthyroidism, changing axis deviation, troponin-I positive and without acute coronary syndrome,” International Journal of Cardiology, vol. 150, no. 3, pp. e85–e88, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Centanni, L. Gargano, G. Canettieri et al., “Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis,” The New England Journal of Medicine, vol. 354, no. 17, pp. 1787–1795, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Vita, G. Saraceno, F. Trimarchi, and S. Benvenga, “Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by proton-pump inhibitors,” Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 12, pp. 4481–4486, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Fallahi, S. M. Ferrari, I. Ruffilli, and A. Antonelli, “Reversible normalization of serum TSH levels in patients with autoimmune atrophic gastritis who received L-T4 in tablet form after switching to an oral liquid formulation: a case series,” BMC Gastroenterology, vol. 16, no. 22, pp. 1–5, 2016. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Cappelli, I. Pirola, L. Daffini et al., “A double-blind placebo-controlled trial of liquid thyroxine ingested at breakfast: results of the TICO study,” Thyroid, vol. 26, no. 2, pp. 197–202, 2016. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Morelli, G. Reboldi, S. Moretti, E. Menicali, N. Avenia, and E. Puxeddu, “Timing of breakfast does not influence therapeutic efficacy of liquid levothyroxine formulation,” Endocrine, vol. 52, no. 3, pp. 571–578, 2016. View at Publisher · View at Google Scholar · View at Scopus
  30. I. Pirola, L. Daffini, E. Gandossi et al., “Comparison between liquid and tablet levothyroxine formulations in patients treated through enteral feeding tube,” Journal of Endocrinological Investigation, vol. 37, no. 6, pp. 583–587, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. I. Pirola, A. M. Formenti, E. Gandossi et al., “Oral liquid L-thyroxine (L-t4) may be better absorbed compared to L-T4 tablets following bariatric surgery,” Obesity Surgery, vol. 23, no. 9, pp. 1493–1496, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Fallahi, S. M. Ferrari, S. Camastra et al., “TSH normalization in bariatric surgery patients after the switch from L-thyroxine in tablet to an oral liquid formulation,” Obesity Surgery, vol. 27, no. 1, pp. 78–82, 2017. View at Publisher · View at Google Scholar
  33. F. Santini, A. Pinchera, A. Marsili et al., “Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases,” Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 1, pp. 124–127, 2005. View at Publisher · View at Google Scholar · View at Scopus